TY - JOUR
T1 - Anxiety, Depression, and Quality of Life after Procedural Intervention for Uterine Fibroids
AU - Wallace, Kedra
AU - Stewart, Elizabeth A.
AU - Wise, Lauren A.
AU - Nicholson, Wanda Kay
AU - Parry, John Preston
AU - Zhang, Shuaiqi
AU - Laughlin-Tommaso, Shannon
AU - Jacoby, Vanessa
AU - Anchan, Raymond M.
AU - Diamond, Michael P.
AU - Venable, Sateria
AU - Shiflett, Amber
AU - Wegienka, Ganesa R.
AU - Maxwell, George Larry
AU - Wojdyla, Daniel
AU - Myers, Evan R.
AU - Marsh, Erica
N1 - Funding Information:
Grant number P50HS023418 from the AHRQ supported this study with funding provided by the PCORI under a memorandum of understanding number 2013-001.
Funding Information:
E.A.S. reports personal fees from Bayer, AbbVie, ObsEva, Myovant, UpToDate, Med Learning Group, PeerView, and PER outside the submitted work and an issued patent ‘‘Methods and Compounds for Treatment of Abnormal Uterine Bleeding’’ 6440445. S.L.-T. reports grants from Bayer and personal fees from Allergan Pharma and UpTo-Date outside the submitted work. V.J. reports grants from Acessa Health outside the submitted work. M.P.D. reports grants from AbbVie, Bayer, and ObsEva outside the submitted work. E.R.M. reports personal fees from AbbVie, Merck, Allergan, and Bayer outside the submitted work. E.M. reports consultant work for Allergan outside the submitted work. All other authors have nothing to disclose.
Publisher Copyright:
© Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.
PY - 2022/3
Y1 - 2022/3
N2 - Background: Quality of life (QOL) and psychological health has been reported to be decreased among women with gynecological conditions such as uterine fibroids (UFs). Materials and Methods: Women enrolled in the Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry, receiving procedural therapy for symptomatic UFs, were eligible for this analysis if they completed a series of health-related QOL surveys administered at three time points (baseline, 6-12 weeks postprocedure, and 1 year postprocedure; n = 1486). Ethical approval for this study was obtained at each recruiting site and the coordinating center (NCT02260752, clinicaltrials.gov). Results: More than 26% (n = 393) of women reported moderate anxiety/depression on the baseline anxiety/depression domain of the Euro-QOL 5-dimension instrument. At both the 6-12 weeks and 1-year postprocedural follow-up, there was significant improvement in the UF QOL symptom severity score (p < 0.001, p < 0.001), the total UF symptom QOL score (p < 0.001, p < 0.001), and the Euro-QOL 5-dimension visual analog scale (p < 0.001, p = 0.004) compared with the preprocedural baseline scores. The reporting of anxiety/depression decreased by 66.4% among women who were at baseline, whereas 5.6% of women previously reporting no anxiety/depression reported anxiety/depression at the 1-year follow-up. Conclusion: UF symptoms were more severe among women reporting anxiety/depression at baseline. At the 1-year follow-up, health-related QOL scores improved among all women and the prevalence of anxiety/depression decreased in most, but not all women, whereas severity of anxiety/depression worsened in a small percentage of women (5.6%). Overall, these results suggest that UF treatment improves symptoms of anxiety/depression associated with symptomatic UFs.
AB - Background: Quality of life (QOL) and psychological health has been reported to be decreased among women with gynecological conditions such as uterine fibroids (UFs). Materials and Methods: Women enrolled in the Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry, receiving procedural therapy for symptomatic UFs, were eligible for this analysis if they completed a series of health-related QOL surveys administered at three time points (baseline, 6-12 weeks postprocedure, and 1 year postprocedure; n = 1486). Ethical approval for this study was obtained at each recruiting site and the coordinating center (NCT02260752, clinicaltrials.gov). Results: More than 26% (n = 393) of women reported moderate anxiety/depression on the baseline anxiety/depression domain of the Euro-QOL 5-dimension instrument. At both the 6-12 weeks and 1-year postprocedural follow-up, there was significant improvement in the UF QOL symptom severity score (p < 0.001, p < 0.001), the total UF symptom QOL score (p < 0.001, p < 0.001), and the Euro-QOL 5-dimension visual analog scale (p < 0.001, p = 0.004) compared with the preprocedural baseline scores. The reporting of anxiety/depression decreased by 66.4% among women who were at baseline, whereas 5.6% of women previously reporting no anxiety/depression reported anxiety/depression at the 1-year follow-up. Conclusion: UF symptoms were more severe among women reporting anxiety/depression at baseline. At the 1-year follow-up, health-related QOL scores improved among all women and the prevalence of anxiety/depression decreased in most, but not all women, whereas severity of anxiety/depression worsened in a small percentage of women (5.6%). Overall, these results suggest that UF treatment improves symptoms of anxiety/depression associated with symptomatic UFs.
KW - ablation
KW - abnormal
KW - bleeding
KW - endometrial
KW - hysterectomy
KW - leiomyoma
UR - http://www.scopus.com/inward/record.url?scp=85126389106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126389106&partnerID=8YFLogxK
U2 - 10.1089/jwh.2020.8915
DO - 10.1089/jwh.2020.8915
M3 - Article
C2 - 34101502
AN - SCOPUS:85126389106
SN - 1540-9996
VL - 31
SP - 415
EP - 424
JO - Journal of Women's Health
JF - Journal of Women's Health
IS - 3
ER -